Investor Murchinson publicly criticized Nano Dimension’s proposed merger with Infinite Epigenetics on June 16, 2026. The investor warned the all-stock deal would heavily dilute existing shareholders and constitutes a misuse of company funds.
Nano Dimension announced the strategic pivot on June 15, 2026, after reviewing approximately 20 potential targets. The transaction transitions the company from digital manufacturing to AI-driven diagnostics, with the combined entity operating as Infinite Epigenetics.
Current Nano Dimension shareholders will retain a meaningful minority stake in the newly formed company. Nano Dimension’s stock price fell significantly on the day of the initial announcement, preceding the public criticism from Murchinson.